Insulet Corporation

260.30
-4.58 (-1.73%)
At close: Mar 27, 2025, 3:59 PM
260.54
0.09%
After-hours: Mar 27, 2025, 06:45 PM EDT

Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.

It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.

Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation
Insulet Corporation logo
Country United States
IPO Date May 15, 2007
Industry Medical - Devices
Sector Healthcare
Employees 3,900
CEO Dr. James R. Hollingshead Ph.D.

Contact Details

Address:
100 Nagog Park
Acton, Massachusetts
United States
Website https://www.insulet.com

Stock Details

Ticker Symbol PODD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001145197
CUSIP Number 45784P101
ISIN Number US45784P1012
Employer ID 04-3523891
SIC Code 3841

Key Executives

Name Position
Dr. James R. Hollingshead Ph.D. President, Chief Executive Officer & Director
Amit Guliani Interim Chief Technology Officer & Group Vice President of Customer-Facing Software Engineering
Ana Maria Chadwick Executive Vice President, Chief Financial Officer & Treasurer
Angela Geryak Wiczek Senior Director of Corporate Communications
Eric Benjamin Executive Vice President, Chief Product & Customer Experience Officer
John Wodick Kapples J.D. Senior Vice President & General Counsel
June Lazaroff Senior Director of Investor Relations
Laetitia Cousin Senior Vice President of Regulatory Affairs, Quality Assurance & Compliance
Lauren Budden Group Vice President, Chief Accounting Officer & Controller
Prem Singh Senior Vice President of Global Operations

Latest SEC Filings

Date Type Title
Mar 26, 2025 4 Filing
Mar 21, 2025 8-K Current Report
Mar 18, 2025 8-K Current Report
Mar 18, 2025 8-K Current Report
Mar 17, 2025 8-K Current Report
Mar 10, 2025 8-K Current Report
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing